|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Fralex Therapeutics |
|---|---|
| Collaborators: |
PharmaNet McDougall Scientific Limited |
| Information provided by: | Fralex Therapeutics |
| ClinicalTrials.gov Identifier: | NCT00450905 |
Purpose
This study is being performed to determine the safety and efficacy of Fralex Neuromodulation Therapy (F-NMT), delivered by the Fralex PRIMA device, in reducing chronic musculoskeletal pain associated with Fibromyalgia.
| Condition | Intervention | Phase |
|---|---|---|
|
Fibromyalgia Pain |
Device: PRIMA Device |
Phase III |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | Randomized Evaluation of a Low-Frequency Investigational Device Employing Neuromodulation Therapy in Patients With Fibromyalgia |
| Estimated Enrollment: | 200 |
| Study Start Date: | March 2007 |
| Estimated Study Completion Date: | December 2008 |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, California | |
| Encinitas, California, United States, 92024 | |
| Garden Grove, California, United States, 92845 | |
| La Jolla, California, United States, 92037 | |
| Lancaster, California, United States, 93534 | |
| Murrieta, California, United States, 92563 | |
| Palmdale, California, United States, 93550 | |
| United States, Florida | |
| Gainsville, Florida, United States, 32610 | |
| West Palm Beach, Florida, United States, 33409 | |
| Winter Park, Florida, United States, 32789 | |
| United States, Kentucky | |
| Lexington, Kentucky, United States, 40503 | |
| United States, Minnesota | |
| Rochester, Minnesota, United States, 55905 | |
| United States, New York | |
| New York, New York, United States, 10003 | |
| Rochester, New York, United States, 14642-8604 | |
| United States, North Carolina | |
| Winston-Salem, North Carolina, United States, 27103 | |
| United States, Pennsylvania | |
| Altoona, Pennsylvania, United States, 16602 | |
| United States, Washington | |
| Seattle, Washington, United States, 98104 | |
| Spokane, Washington, United States, 99216 | |
| Canada, Ontario | |
| Hamilton, Ontario, Canada, L8N 3Z5 | |
| Ottawa, Ontario, Canada, K1H 1A2 | |
| Toronto, Ontario, Canada, M9W 4L6 | |
| Toronto, Ontario, Canada, M2N 6K7 | |
More Information
| ClinicalTrials.gov Identifier: | NCT00450905 History of Changes |
| Other Study ID Numbers: | F06001 |
| Study First Received: | March 21, 2007 |
| Last Updated: | October 3, 2008 |
| Health Authority: | United States: Food and Drug Administration; Canada: Health Canada |
|
Chronic musculoskeletal pain secondary to Fibromyalgia |
|
Fibromyalgia Myofascial Pain Syndromes Muscular Diseases Musculoskeletal Diseases |
Rheumatic Diseases Neuromuscular Diseases Nervous System Diseases |